PMGC Holdings (ELAB) Non-Current Debt (2024 - 2026)

PMGC Holdings (ELAB) posted Non-Current Debt of $85000.0 for Q1 2026, little changed sequentially from $85000.0 in Q4 2025.

PMGC Holdings (ELAB) Non-Current Debt (2024 - 2026) Analysis & Trends

PMGC Holdings has reported Non-Current Debt for 3 years, with the latest figure at $85000.0 in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $85000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85000.0 (changed N/A YoY) and the FY2025 annual result came in at $85000.0, changed N/A from the prior year.
Non-Current Debt was little changed at $85000.0 in Q1 2026 per ELAB's latest filing, from $85000.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $869711.0 in Q3 2024 and troughed at $85000.0 in Q4 2025.
A 3-year average of $407325.8 and a median of $491557.0 in 2024 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00	-

Download Data